Xynomic Pharmaceuticals Holdings, Inc. (NasdaqCM:XYN) announced that it has entered into securities purchase agreement to issue minimum 1,315,789 units at issue price of $3.8 per unit for gross proceeds of $5,000,000 of units and maximum of 3,947,368 units at issue price of $3.8 per units for gross proceeds of $15,000,000 on July 10, 2019. Each unit consists of one common share of face value of $0.0001 per share and one-half warrant. Each whole warrant can be exercised to purchase one common share of the company at exercise price of $7 per share for a period of three years from the date of the issuance. The transaction will close no later than September 30, 2019. If the first closing does not occur within six months after the date of agreement unless the applicable investor and the company have agreed upon a later first closing date with respect to the applicable investor, the agreement shall terminate automatically at the end of such six month period. The minimum amount per investor is $10,000. The aggregate maximum number of units to be sold in the first closing and all subsequent closing shall be 3,947,368 units. The company shall incur expenses related to the transaction which shall not exceed $5,000. On August 30, 2019, the company announced that investors will be granted demand registration rights. The holders of a majority of all of the existing registrable securities, as defined in the amended and restated security purchase agreement may demand at any time: after the earlier of one year after the date of the agreement and 180 days after the effective date of the registration statement for a public offering; or at any time when the company is eligible to use a Form S-3 registration statement, for registration under the Securities Act. The demand registration rights are subject to certain exceptions set forth in the amended agreement including that the company shall not be obliged to effect more than two demand registration in any one-year period.